The Commonwealth of Massachusetts

PRESENTED BY:

Patricia A. Haddad

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:

An Act relative to the modernization of optometric patient care.

PETITION OF:

NAME:	DISTRICT/ADDRESS:
Patricia A. Haddad	5th Bristol
Sean Garballey	23rd Middlesex
Sarah K. Peake	4th Barnstable
Thomas M. Stanley	9th Middlesex
Geraldine Creedon	11th Plymouth
Thomas J. Calter	12th Plymouth
Anne M. Gobi	5th Worcester
Linda Dean Campbell	15th Essex
William N. Brownsberger	24th Middlesex
Paul J. Donato	35th Middlesex
Alice K. Wolf	25th Middlesex
Dennis A. Rosa	4th Worcester
Kevin Aguiar	7th Bristol
Ruth B. Balser	12th Middlesex
Michael D. Brady	9th Plymouth
Christine E. Canavan	10th Plymouth
Stephen R. Canessa	12th Bristol

Gailanne Cariddi	1st Berkshire
Tackey Chan	2nd Norfolk
Nick Collins	4th Suffolk
Sean Curran	9th Hampden
Mark Cusack	5th Norfolk
James J. Dwyer	30th Middlesex
Carolyn C. Dykema	8th Middlesex
John V. Fernandes	10th Worcester
William C. Galvin	6th Norfolk
Denise Garlick	13th Norfolk
Thomas A. Golden, Jr.	16th Middlesex
Kate Hogan	3rd Middlesex
John D. Keenan	7th Essex
David Paul Linsky	5th Middlesex
Paul McMurtry	11th Norfolk
Richard T. Moore	Worcester and Norfolk
James M. Murphy	4th Norfolk
Michael J. Rodrigues	First Bristol and Plymouth
George Ross	2nd Bristol
Byron Rushing	9th Suffolk
Jeffrey Sánchez	15th Suffolk
Frank I. Smizik	15th Norfolk
Todd M. Smola	1st Hampden
Joseph F. Wagner	8th Hampden
Brian Ashe	2nd Hampden
Antonio F. D. Cabral	13th Bristol
James M. Cantwell	4th Plymouth
Thomas P. Conroy	13th Middlesex
Edward Coppinger	10th Suffolk
Robert F. Fennell	10th Essex
Donald F. Humason, Jr.	4th Hampden
Peter V. Kocot	1st Hampshire
Stephen Kulik	1st Franklin
Angelo J. Puppolo, Jr.	12th Hampden
Kathi-Anne Reinstein	16th Suffolk
Theodore C. Speliotis	13th Essex
Ellen Story	3rd Hampshire
Walter F. Timilty	7th Norfolk
David M. Torrisi	14th Essex

James E. Vallee	10th Norfolk
Chris Walsh	6th Middlesex
Martin J. Walsh	13th Suffolk

HOUSE No. 02348

By Ms. Haddad of Somerset, a petition (accompanied by bill, House, No. 2348) of Patricia A. Haddad and others relative to optometric patient care. Public Health.

The Commonwealth of Massachusetts

In the Year Two Thousand Eleven

An Act relative to the modernization of optometric patient care.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- 1 SECTION 1. Section 1 of chapter 94C of the General Laws, as appearing in the 2008 Official
- 2 Edition, is hereby amended by striking out, in line 244, the words "sections 66 and 66B" and
- 3 inserting in place thereof the following words:- either sections 66 and 66B or sections 66 and

4 66C.

- 5 SECTION 2. Section 7 of said chapter 94C, as so appearing, is hereby amended by striking out,
- 6 in line 191, the words "sections 66 and 66B" and inserting in place thereof the following words:-
- 7 either sections 66 and 66B or sections 66 and 66C.
- 8 SECTION 3. Section 9 of said chapter 94C, as so appearing, is hereby amended by striking out,
- 9 in line 2, the words "sections 66 and 66B" and inserting in place thereof the following words:-
- 10 either sections 66 and 66B or sections 66 and 66C.

SECTION 4. Said section 9 of said chapter 94C, as so appearing, is hereby further amended by
inserting after the word "podiatrist", in line 55, the following word:-, optometrist.

SECTION 5. Section 66 of chapter 112 of the General Laws, as so appearing, is hereby
amended by inserting after the word "utilization", in line 7, the following words:- and
prescription.

SECTION 6. Said section 66 of said chapter 112, as so appearing, is hereby further amended by
striking out, in line 12, the words " and 66B" and inserting in place thereof the following words:, 66B and 66C.

SECTION 7. The first paragraph of section 66A of said chapter 112, as so appearing, is hereby
amended by adding the following sentence:- A registered optometrist may utilize epinephrine,
adrenaline or other agents used in the percutaneous treatment of anaphylaxis.

SECTION 8. Section 66B of said chapter 112, as so appearing, is hereby amended by inserting after the words "injection," in line 13, the third time it appears, the following words:-, except for the utilization of epinephrine, adrenaline or other agents used in the percutaneous treatment of anaphylaxis.

26 SECTION 9. Said chapter 112 is hereby further amended by inserting after section 66B the 27 following section:-

Section 66C. (a) A registered optometrist, qualified by examination for practice under section 68 after January 1, 2009, duly certified in accordance with section 68C and duly registered to issue written prescriptions in accordance with paragraph (h) of section 7 of chapter 94C may, for the purpose of diagnosing, preventing, correcting, managing or treating ocular diseases, including

glaucoma and ocular abnormalities of the human eye and adjacent tissue, utilize and prescribe 32 topical and oral therapeutic pharmaceutical agents used in the practice of optometry as defined in 33 section 66 and described in Title 21 U.S.C. Section 812 or in chapter 94C, including those 34 placed in schedules III, IV, V and VI by the commissioner pursuant to section 2 of chapter 94C 35 and including the utilization of epinephrine, adrenalin, or other agents used in the percutaneous 36 37 treatment of anaphylaxis. Nothing in this section shall be construed to permit optometric 38 utilization or prescription of: (a) therapeutic pharmaceutical agents for the treatment of systemic diseases; (b) invasive surgical procedures; or (c) pharmaceutical agents administered by 39 40 subdermal injection, intramuscular injection, intravenous injection, subcutaneous injection or retrobulbar injection, except as authorized above for the percutaneous treatment of anaphylaxis. 41 The pharmaceutical agents from schedule III shall be limited to the narcotic analgesics and shall 42 43 not include the use of hallucinogenic substances or anabolic steroids. Oral steroid treatment required beyond 14 days shall be continued only in consultation with the patient's physician. 44

(b) If, during the course of examining or treating a patient with the aid of a diagnostic or
therapeutic pharmaceutical agent, an optometrist, exercising professional judgment and that
degree of expertise, care and knowledge ordinarily possessed and exercised by optometrists
under like circumstances, determines the existence of the signs of previously unevaluated disease
which requires treatment not included in the scope of optometric practice as set forth in section
66, such optometrist shall refer the patient to a licensed physician or other qualified health care
practitioner. Optometrists may utilize and prescribe nonlegend agents.

52 (c) Nothing in this section shall prevent a qualified optometrist from serving as an approved53 investigator in a clinical trial evaluating such drugs.

(d) If a patient exam shows newly diagnosed congenital glaucoma or if, during the course of
examining, managing or treating a patient with glaucoma, surgical treatment is indicated, an
optometrist shall refer that patient to a qualified physician for treatment.

(e) Optometrists licensed under this chapter 112 and the board of registration in optometry shall 57 participate in appropriate state or federal reports or data collection efforts relative to patient 58 safety and medical error reduction coordinated by the Betsy Lehman center for patient safety and 59 60 medical error reduction established in section 16E of chapter 6A. Every insurer or risk management organization which provides insurance to an optometrist licensed under this chapter 61 112 shall make an annual report to the center. The report shall list the top 10 categories of losses, 62 claims or actions for damage for personal injuries alleged to have been caused by error, omission 63 or negligence in the performance by optometrists of services the company incurred during the 64 65 previous calendar year. Reports shall include completed cases and settlements only and shall not include information identifying providers or patients. Reports shall be provided to the center at 66 its request under annual timelines and reporting requirements established by the center with the 67 input of the advisory committee established in section subsection (c) of said section 16E of said 68 chapter 6A. The center shall use this information in the development of evidence-based best 69 practices to reduce errors and enhance patient safety as required by subsection (e) of said section 70 16E of said chapter 6A to increase awareness of error prevention strategies through public and 71 professional education as required by that subsection. 72

73 SECTION 10. Said chapter 112 is hereby further amended by inserting after section 68B the74 following section:-

Section 68C (a) The board of registration in optometry shall administer an examination designed 75 to measure the qualifications necessary to safely utilize and prescribe therapeutic pharmaceutical 76 agents defined in subsection (a) of section 66C. Such examination shall be held in conjunction 77 with examinations provided in sections 68, 68A and 68B and shall include any portion of the 78 79 examination administered by the National Board of Examiners in Optometry or other appropriate 80 examinations covering the subject matter of therapeutic pharmaceutical agents. Nothing shall prohibit the board from administering 1 examination to measure the qualifications necessary 81 under sections 68, 68A, 68B and 68C. The board shall, subsequent to January 1, 2009, only 82 83 qualify for practice in accordance with said sections 68, 68A, 68B and 68C; and any applicant that presents satisfactory evidence that he has graduated from a school or college of optometry, 84 approved by the board, subsequent to January 1, 2009 shall have satisfied all the requirements of 85 86 sections 68, 68A, 68B and 68C.

(b) Examination for the utilization and prescription of therapeutic pharmaceutical agents placed 87 under schedules III, IV, V and VI by the commissioner pursuant to section 2 of chapter 94C and 88 defined in subsection (a) of section 66C shall, upon application, be open to an optometrist 89 90 registered under section 68, 68A or 68B and to any person who meets the qualifications for examination under sections 68, 68A and 68B. Each such applicant, registered as an optometrist 91 92 under said section 68, 68A or 68B, shall possess a current Massachusetts controlled substance registration for the use of topical pharmaceutical agents described in section 66B and placed 93 under schedule VI by the commissioner pursuant to section 2 of chapter 94C and shall furnish to 94 95 the board of registration in optometry evidence of the satisfactory completion of 40 hours of didactic education and 20 hours of supervised clinical education relating to the utilization and 96 prescription of therapeutic pharmaceutical agents defined in subsection (a) of section 66C. Such 97

98 education shall be administered by the Massachusetts Society of Optometrists, shall be
99 accredited by a college of optometry or medicine and shall otherwise meet the guidelines and
100 requirements of the board of registration in optometry. The board of registration in optometry
101 shall provide to the department of public health and each successful applicant a certificate of
102 qualification in the utilization and prescription of all therapeutic pharmaceutical agents as
103 defined in said subsection (a) of said section 66C.

(c) An optometrist licensed in another jurisdiction shall, after January 1, 2009, be deemed an 104 applicant under section 68C by the board of registration in optometry. An optometrist licensed in 105 another jurisdiction may submit evidence to the board of registration in optometry of practice 106 107 equivalent to that required in section 68, 68A or 68B and the board, at its discretion, may accept 108 such evidence in order to satisfy any of the requirements of this section. An optometrist licensed 109 in another jurisdiction to utilize and prescribe therapeutic pharmaceutical agents substantially 110 equivalent to those placed under schedules III, IV, V and VI by the commissioner pursuant to section 2 of chapter 94C and defined in subsection (a) of section 66C may submit evidence to the 111 board of registration in optometry of equivalent didactic and supervised clinical education in 112 order to satisfy all the requirements of this section. 113

(d) A licensed optometrist who has completed a Council on Optometric Education- approved, post-graduate residency program after July 31, 1997 may submit an affidavit to the board of registration in optometry from their residency supervisor or the director of residencies at the affiliated college of optometry attesting that an equivalent level of instruction and supervision was completed in order to satisfy all the requirements of this section.

- 119 (e) As a requirement of license renewal, an optometrist licensed under this section shall submit to
- 120 the board of registration in optometry evidence attesting to the completion of 3 hours of
- 121 continuing education specific to glaucoma.
- 122 SECTION 11. Within 90 days after the effective date of this act, the department of public health
- 123 and the board of registration in optometry shall promulgate the rules and regulations required by
- 124 sections 1, 7, and 9 of chapter 94C of the General Laws and sections 66, 66A, 66B, 66C and 68C
- 125 of chapter 112 of the General Laws.